50 results about "Barbiturate" patented technology

The invention discloses a method which can carry out qualitative screening to 242 compounds (drugs or toxicants) simultaneously. A mode of liquid chromatogram-mass spectrometry (LC-MS/MS) multi-reaction monitoring (MRM) is adopted to carry out determinedness to objects by two pairs of parent ion-daughter ion pair and retention time. The 242 drugs or toxicants comprise toxic products such as opioids, amphetamine and cocaines and the like, bromazepam such as benzodiazepines and barbiturates, and common drugs, alkaloid, pesticide (including organophosphates, carbamates, pyrethroid pesticide residues and organochlorine pesticide), weed killer, raticide and the like.

Opiates, amphetamines, barbiturates and other drugs such as benzodiazepines are extensively abused or misused and are frequently the cause of death by overdosing. These drugs are also prone to oxidation and the final degradation products depend on the reactants and the reaction conditions. This invention describes the use of inactivating agents such as permanganates, peroxides, persulfates, bismuthates, periodates or other oxidants in a dosage form as an approach to minimize abuse and overdose. The product is designed such that the inactivating agent is released if there is an attempt to extract the drug from the formulation or in cases of overdose. Once released, the inactivating agent quickly degrades the drug and converts it into inactive compounds. Since the reactants (drug and inactivating agent) are incompatible in situations of normal drug usage, they are kept separated within the vehicle of the invention, but released for interaction in case of misuse. A catalyst may be included in the formulation to facilitate the reaction.

The invention discloses a method for detecting 33 kinds of narcotic drugs in urine by liquid chromatography-tandem mass spectrometry, which is characterized by comprising the following steps: carrying out extraction and purification on samples by using a liquid-liquid extraction method, adding a sodium hydroxide solution into the obtained object so as to realize albuminous degeneration and pH-value adjustment of the obtained object, and adding ethyl acetate into the obtained mixture so as to carry out extraction on the obtained mixture through liquid-liquid extraction, then obtaining to-be-tested samples; carrying out determination on the to-be-tested samples by using a liquid chromatography-tandem quadrupole mass spectrometer, wherein, except for that barbiturates in the to-be-tested samples are analyzed in a negative ion mode, the other compounds in the to-be-tested samples are analyzed in a positive ion mode; and through taking the relative retention time of each narcotic drug and the abundance ratio of a monitoring ion pair of each narcotic drug as the qualitative basis, calculating the residual quantity of each narcotic drug in the samples according to the peak area or peak height of each narcotic drug. By using the method disclosed by the invention, 33 kinds of narcotic drugs can be analyzed at one time, and the test cost is reduced, meanwhile, the method is strong in pertinence, simple in operation, fast in detection speed, wide in detection surface, and easy to popularize and apply. The method can be used in the quick detection and positive result confirmation of entry-exit inspection and quarantine bureaus, disease control centers and public security departments.

The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative.

Compound methilanin thiamin is used to assist treat that acute and chronic hepatitis, fatty liver, early cirrhosis of liver, toxic hepatitis brought by arsenic and barbiturate and other diseases in clinic. But, there is only liquid drugs injection supplied in market at present. Compound methilanin thiamin is unstable to heat; thiamin is easy to decompose on condition of solution, opacification or precipitate; after sterilization at high temperature, content of thiamin in liquid drugs injection will decrease for decomposition; meantime the storage and transport for liquid drugs injection is not convenient. The invention overcomes the shortage of methilanin thiamin liquid drugs injection, increases stability of drug, is propitious to transport and storage; and avoids freezing easily in winter and affecting quality of drug, prolongs drug storage life, improves quality of drug, in order to treat patients more safely and effectively.

This invention relates to a tamper resistant medication dispenser. The medication dispenser is programmed to dispense a specified dose of medication at a specified interval. The medication dispenser prevents direct access to the medication by the patient. The medication is dispensed to the patient dissolved in a large volume of liquid to prevent intravenous and intranasal abuse. The medication dispenser can be equipped with a self destruct mechanism when tampered with and have the ability to record video for subsequent monitoring, the actual medication ingestion of the medication infused liquid by the patient. It is especially useful for controlled substances which have high potential for abuse such as opioids, benzodiazepines and barbiturates and anesthetic agents and when patient compliance with medications is necessary such as medications for the treatment of contagious diseases.

A local system for the release of active principle is described which consis ts of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxid e or barium sulphate and one or more pharmaceutical active principles, in particular antibiotics, and which are produced by radical polymerisation, radical polymerisation activators effective in the temperature range of 10-80 .degree.C or residues of these polymerisation activators from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein. A process for the production of the local system for the release of active principle in the case of which a) a paste is produced by mixing methyl methacrylate, polymethyl methacrylat e or poly-methyl methacrylate co-methyl acrylate, zirconium dioxide and/or barium sulphate, o ne or more pharmaceutical active principles and a thermally decomposing radical initiator, the paste having a viscosity such that it cannot be deformed at room temperature by the effect of gravity; b) the paste is injection moulded by an injection moulding device without heating at room temperature into approximately spherical or rotation-symmetrical bodies or t he approximately spherical or rotation symmetrical bodies are injection-moulded onto a wire; c) the bodies are heated to a temperature at which the polymerisation initiator decomposes.

The invention provides a preparation method of 5-methyl-5-phenylbarbituric acid. The method comprises the following two steps: A, performing a reaction on diethyl alpha-methyl-alpha-phenylpropanedioate (referred to a compound III) and urea in the presence of a methanol solution of sodium methoxide to prepare sodium 5-methyl-5-phenyl barbiturate (referred to a compound II); and performing acidification on the compound (II) by using hydrochloric acid to obtain a crude product of the compound (I); and B, performing recrystallization on the crude product of the compound (I) obtained in the step Ain an ethanol aqueous solution to obtain a fine product of the compound (I). According to the preparation method provided by the invention, the reaction conditions are easy to control, the product quality is stable, the obtained crude product has a content of 99.0% or more by HPLC, and after primary purification, the purity of the product by the HPLC is >99.8%; and the production costs are low, and the method is more suitable for industrial production.

The invention discloses a purple fluorescent material and a preparation method thereof. The preparation method comprises the following step: enabling barbituric acid which has -CONHCO- and COCH2CO- structures and deionized water to perform chemical reaction with cadmium ions which have optical activities so as to prepare a cadmium barbiturate compound with a certain spatial structure, wherein the molecular formula of the compound is C8H10N4O8Cd; the molecular weight is 402.59; a crystal system is orthorhombic; the space group is Ibam; lattice parameters are as follows: a is equal to 12.5498 angstroms, b is equal to 13.967 angstroms, c is equal to 6.9470 angstroms, alpha is equal to 90.00 degrees, beta is equal to 90.00 degrees, and gamma is equal to 90.00 degrees. The compound fluorescent material disclosed by the invention contains rich optical activities and uniquely coordinated and configured Cd (II) ions and nitrogen-containing heterocyclic rings, is beneficial to electron transition and energy transmission, has unique photoelectric activities, shows unique purple fluorescence emission performance, and can be applied as the fluorescent material.

Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

The invention belongs to the field of medicinal chemistry, and discloses a barbiturate compound, a preparing method and application thereof. Specifically, the invention relates to the compound as shown in formula I, and a medicinal usage thereof as a selective LSD1 reversible inhibitor, particular to the application in preparing of antitumor medicine. A test shows that the compound in formula I can efficiently reversibly inhibit LSD1 activity, and has a weak inhibition action for homologous proteins MAO-A and MAO-B, can intensively induce differentiation of leukemia cell NB4 and obviously enhance the methylation level of primers H3K4me1 and H3K4me2 of the LSD1.

The invention discloses a method for detecting 4 types of barbiturate sedatives in raw milk. The method comprises the following steps: mixing, shaking and performing ultrasound on raw milk to be detected and acetonitrile solution, adding inorganic salt A, and performing centrifugation; drying supernatant through nitrogen gas, and fixing the volume through acetonitrile aqueous solution, so as to purify the supernatant; ensuring that acid is formic acid or acetic acid; prewashing a column through methanol and acetonitrile aqueous solution, performing column chromatography isolation on the solution to be purified, with constant volume, washing the column through ultrapure water, and performing vacuum drying; performing eluting through methylene chloride, controlling the flow velocity, drying eluent through nitrogen gas, fixing the volume on the acetonitrile aqueous solution, so as to be used for a machine; performing high-efficiency liquid chromatogram-mass spectrogram combination detection and analysis on raw milk solution to be detected obtained in a pretreatment method. The pretreatment method in the detection method can effectively improve the extraction efficiency of the barbiturate sedatives in the raw milk, and can further effectively improve the recovery percent of the barbiturate sedatives in the raw milk, the method is simple, economical and reliable, the influence on the raw milk by ground substance is effectively reduced, and the sensibility, the recurrence rate and the recovery ratio are good.

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

The invention provides application of a benzylidene barbiturate compound in serving as a PCSK9 antagonist, and further provides application of the benzylidene barbiturate compound in reducing the low-density lipoprotein. The invention provides a small-molecule benzylidene barbiturate compound serving as the PCSK9 antagonist, and the benzylidene barbiturate compound can effectively reduce the concentration of low-density lipoprotein.

The present invention provides a therapeutic agent for substance dependence, which prevents relapse/recurrence of compulsive substance-taking behavior based on craving for addictive substances such as stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, cocaine, hemp, cannabis, alcohol, or volatile organic solvents. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is useful as a therapeutic agent for substance dependence, which prevents relapse/recurrence of compulsive substance-taking behavior associated with craving for addictive substances.

The invention discloses a Chinese and western medicine formula for treating insomnia. The Chinese and western medicine formula comprises the following raw materials in parts by weight: 20-30 parts ofsporoderm-broken ganoderma lucidum spore powder, 10-20 parts of Peru maca, 5-15 parts of acanthopanax and 8-12 parts of gamma-aminobutyric acid. Meanwhile, the invention also provides a preparation method of a Chinese and western medicine for treating insomnia. According to the Chinese and western medicine formula disclosed by the invention, the Peru maca, the sporoderm-broken ganoderma lucidum spore powder and the acanthopanax are combined and matched according to different dosages, the effects of calming and hypnotizing are enhanced by utilizing the complementary effect of the components, and the central inhibition effect of barbital medicines can be enhanced. Meanwhile, excessive nerve excitation can be inhibited, the Chinese and western medicine formula is helped to enter a sleep state, and the effect of improving sleep is achieved. The Chinese and western medicine formula is suitable for people suffering from long-term insomnia, people who easily feel anxious and are poor in sleepquality and people with low immunity.